Posts Tagged ‘PLATO’

June 27th, 2011

Asprin Dosage in U.S. May Explain Disparity in Ticagrelor Results in PLATO

Although the PLATO trial demonstrated the overall superiority of ticagrelor (Brilinta, AstraZeneca) to clopidogrel in more than 18,000 acute coronary syndrome patients worldwide, approval of the drug in the U.S. has been delayed because of ticagrelor’s lack of effect in the prespecified subgroup of patients from North America. Now, two analyses of the trial, presented […]